About 1.9 million people in the U.S. have type 1 diabetes mellitus (T1DM), a chronic autoimmune condition that increases the risk of serious complications and affects quality of life. New technologies can improve glycemic control for patients requiring multiple insulin injections daily, but healthcare providers (HCPs) often struggle to create personalized treatment plans using these devices.
This activity will feature expert speakers who will:
- Evaluate new technologies for managing T1DM, including glucose monitoring and automated insulin delivery systems for both adults and children.
- Discuss how to select and implement diabetes technology for personalized treatment plans.
- Address barriers to using diabetes technology and emphasize the importance of patient education and shared decision-making for optimal T1DM management.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org
Satish K. Garg, MD, Editor-in-Chief, Diabetes Tech. and Therap., Professor of Medicine and Pediatrics, Babara Davis Center for Diabetes, University of Colorado.
Halis Akturk, MD, Associate Professor of Medicine and Pediatrics with a focus on improving glycemic control with advanced diabetes technologies and therapeutics in people with type 1 diabetes. Babara Davis Center for Diabetes, University of Colorado.Gregory P. Forlenza, MD, Associate Professor of Pediatrics, Director of Pediatrics Technology Research, Babara Davis Center for Childhood Diabetes, University of Colorado.
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Satish K. Garg, MD: Advisory Boards, Consulting Fees: Medtronic, Novo Nordisk, Embecta, Eli Lilly, Abbott; Research Grants: Eli Lilly, Novo Nordisk, Medtronic, Dario, T1D Exchange and Dexcom, DiasomeHalis Akturk, MD: Research Support and Honorarium Through the University of Colorado: Medtronic, Tandem Diabetes, Dexcom.
Gregory P. Forlenza, MD: Research Support: Medtronic, Dexcom, Abbott, Tandem, Insulet, Beta Bionics, Lilly, Sequel; Consulting: Speaking, Ad Board: Medtronic, Dexcom, Abbott, Tandem, Insulet, Beta Bionics, Lilly, Sequel
The following committee member who planned and reviewed content for this activity reported the following financial relationships:
Milay Luis Lam, MD: The obesity society, member, chair of the clinical management section, no payment
Speaker for Sanofi, educational non product promotion
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grants from Mannkind and Medtronic.